Novel treatment for Fabry disease: IV administration of plant derived alpha-gal-A enzyme safety and efficacy interim report
Year: 2016
Type: article
Study design: Observational Study
Authors: Derralynn Hughes, Simeon Boyd, Pilar Giraldo, Derlis Gonzalez, Myrl Holida, Ozlem Goker-Alpan, Gustavo Megawa, Mohamed Atta, Kathy Nicholls, Raphael Schiffmann, Ahmad Tuffaha, Jeannie Visootsak, Laura Barisoni, Robert Colvin, J. Charles Jannette, Sari Alon, Jenny Krupko, Mali Szlaifer, Einat Brill-Almon, Raul Chertkoff
Institutions: University College London, University of California Davis Medical Center, Instituto Privado de Hematología e Investigación Clínica, University of Iowa Hospitals and Clinics, O&O Alpan (United States), Johns Hopkins University, The Royal Melbourne Hospital, University of Kansas Medical Center, Emory University Hospital, University of Miami, Massachusetts General Hospital, University of North Carolina at Chapel Hill, Protalix BioTherapeutics (Israel)
Language: English
Subfield: Physiology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2260718243